



(43) International Publication Date
12 September 2014 (12.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/138452 A1

- (51) **International Patent Classification:**
C07C 275/30 (2006.01) *A61K 31/17* (2006.01)
- (21) **International Application Number:**
PCT/US2014/021345
- (22) **International Filing Date:**
6 March 2014 (06.03.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/774,822 8 March 2013 (08.03.2013) US
- (71) **Applicant:** ALLERGAN, INC. [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).
- (72) **Inventors:** MALONE, Thomas C.; 49 Trailwood, Irvine, California 92620 (US). HULL III, Clarence E.; 22616 Galilea, Mission Viejo, California 92692 (US).
- (74) **Agents:** BANERJEE, Krishna et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) **Title:** KINASE INHIBITORS

(57) **Abstract:** The present invention relates to compounds of formula I or a pharmaceutically acceptable salts thereof; wherein the variables R¹-R⁵, Ar¹, and X are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.



WO 2014/138452 A1

KINASE INHIBITORS

By Inventors: Thomas C. Malone and Clarence E. Hull, III

5

RELATED APPLICATIONS

This application claims the benefit of United States Provisional Patent Application Serial No. 61/774,822 filed March 08, 2013, the disclosure of which is hereby incorporated in its entirety herein by reference.

10

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to novel compounds capable of modulating, regulating
15 and/or inhibiting tyrosine kinase signal transduction. The present invention is also directed to methods of regulating, modulating or inhibiting tyrosine kinases, whether of the receptor or non-receptor class, for the prevention and/or treatment of disorders related to unregulated tyrosine kinase signal transduction, including cell growth, metabolic, and blood vessel proliferative disorders.

20

Description of the Related Art

Protein tyrosine kinases (PTKs) comprise a large and diverse class of proteins having enzymatic activity. The PTKs play an important role in the control of cell growth and
25 differentiation.

For example, receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and
30 phosphorylation. Binding sites are thereby created for intracellular signal transduction

molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic homeostasis, and responses to the extracellular microenvironment).

5 With respect to receptor tyrosine kinases, it has been shown also that tyrosine phosphorylation sites function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Several intracellular substrate proteins that associate with receptor tyrosine kinases (RTKs) have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates
10 which lack such domain but serve as adapters and associate with catalytically active molecules. The specificity of the interactions between receptors or proteins and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine
15 residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. These observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important
20 regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

Aberrant expression or mutations in the PTKs have been shown to lead to either uncontrolled cell proliferation (e.g. malignant tumor growth) or to defects in key
25 developmental processes. Consequently, the biomedical community has expended significant resources to discover the specific biological role of members of the PTK family, their function in differentiation processes, their involvement in tumorigenesis and in other diseases, the biochemical mechanisms underlying their signal transduction pathways activated upon ligand stimulation and the development of novel drugs.

30

Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular).

The receptor-type tyrosine kinases (RTKs) comprise a large family of transmembrane
5 receptors with diverse biological activities. The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses. The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. A more detailed discussion of receptor
10 and non-receptor tyrosine kinases is provided in Cowan-Jacob Cell Mol. Life Sci., 2996, 63, 2608-2625 which is incorporated herein by reference.

There are a number of examples where RTK kinases, have been found to be involved in cellular signaling pathways leading to pathological conditions, including exudative age-related macular degeneration (Ni et al. Ophthalmologica 2009 223 401-410; Chappelow
15 et al. Drugs 2008 68 1029-1036), diabetic retinopathy (Zhang et al., Int. J. Biochem. Cell Biol. 2009 41 2368-2371), cancer (Aora et al. J. Path. Exp. Ther. 2006, 315, 971), psoriasis (Heidenreich et al Drug News Perspective 2008 21 97-105), rosacea (Smith, J. R., V. B. Lanier, et al. Br J Ophthalmol 2007, **91**(2): 226-229) and hyper immune
20 response. In ophthalmic diseases such as exudative age-related macular degeneration and diabetic retinopathy aberrant activation of VEGF receptors can lead to abnormal blood vessel growth. The importance of VEGFR signaling in the exudative age-related macular degeneration disease process is evident by the clinical success of multiple anti-VEGF targeting agents including Lucentis[®], Avastin[®], and EYLEA[™] (Barakat et al.,
25 Expert Opin. Investig. Drugs 2009, 18, 637). Recently it has been suggested that inhibition of multiple RTK signaling pathways may provide a greater therapeutic effect than targeting a single RTK signaling pathway. For example in neovascular ocular disorders such as exudative age-related macular degeneration and diabetic retinopathy the inhibition of both VEGFR and PDGFR β may provide a greater therapeutic effect
30 in by causing regression of existing neovascular blood vessels present in the disease (Adamis et al., Am. J. Pathol. 2006 168 2036-2053). In cancer inhibition of multiple


RTK signaling pathways has been suggested to have a greater effect than inhibiting a single RTK pathway (DePinho et al., Science 2007 318 287-290; Bergers et al. J. Clin Invest. 2003 111 1287-1295).

- 5 The identification of effective small compounds which specifically inhibit signal transduction by modulating the activity of receptor and non-receptor tyrosine kinases to regulate and modulate abnormal or inappropriate cell proliferation is therefore desirable and one object of this invention.
- 10 The above references are hereby incorporated by reference in their entirety for the purpose of disclosing starting materials and methods for the preparation thereof, screens and assays to determine a claimed compound's ability to modulate, regulate and/or inhibit cell proliferation, indications which are treatable with said compounds, formulations and routes of administration, effective dosages, etc.

15

BRIEF SUMMARY OF THE INVENTION

- The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction by blocking the VEGF and/or
- 20 PDGF receptors. Such compounds are useful for the treatment of diseases related to unregulated tyrosine kinase signal transduction, including vascular proliferative disorders such as diabetic retinopathy, age-related macular degeneration and retinopathy of prematurity.
- 25 In one illustrative embodiment, the compounds of the present invention have the following general formula I:



30

I

wherein:

R^1 is selected from the group consisting of hydrogen and lower alkyl;


5 R^2 is selected from the group consisting of hydrogen and lower alkyl;

R^3 is selected from the group consisting of hydrogen, alkyl, e.g. lower alkyl, aryl and substituted aryl, e.g. carbocyclic aryl and substituted carbocyclic aryl;

10 R^4 is selected from the group consisting of hydrogen, C_1 to C_8 alkyl, $(CR^6R^7)_pNR^8R^9$, $(CR^6R^7)_pC(O)OR^8$ and $(CR^6R^7)_pOR^8$

Ar^1 is aryl, e.g. carbocyclic aryl or heteroaryl;

X is



R^5 is aryl, e.g. carbocyclic aryl or heteroaryl, wherein said carbocyclic aryl or heteroaryl may be optionally substituted with lower alkyl, halogen, or trifluoromethyl;

20 R^6 is selected from the group consisting of hydrogen, lower alkyl, halogen, trifluoromethyl and hydroxyl;

R^7 selected from the group consisting of hydrogen, lower alkyl, halogen, trifluoromethyl and hydroxyl;

25

R^8 is selected from the group consisting of hydrogen and lower alkyl

R^9 is selected from the group consisting of hydrogen and lower alkyl, or

R^8 and R^9 may be taken together with N to form a heterocyclic ring;

p is an integer of from 1 to 6; and

- 5 prodrugs, pharmaceutically acceptable salts, racemic mixtures and enantiomers of said compound.

In one embodiment, R^1 is hydrogen.

- 10 In another embodiment, R^2 is hydrogen.

In another embodiment, R^3 is selected from the group consisting of hydrogen, phenyl and alkyloxyphenyl, e.g. methoxyphenyl.

- 15 In another embodiment, R^4 is hydrogen;

In another embodiment, Ar^1 is phenyl.

In another embodiment, X is $-HN-C(O)-NH-$.

20

In another embodiment, R^5 is selected from the group consisting of phenyl and halo-substituted and halo lower alkyl-substituted phenyl, e.g. fluorophenyl, trifluoromethylphenyl and fluoro, trifluoromethylphenyl.

- 25 In another embodiment, R^5 is a fluoro, trifluoromethylphenyl, e.g. 2- fluoro-5-trifluoromethylphenyl.

In another embodiment, said compound has an IC_{50} value for compound inhibition in the VEGFR2 Kinase Assay of less than 1000 nM.

30

Compounds of formula I are useful as kinase inhibitors. As such, compounds of formula I will be useful for treating diseases related to unregulated tyrosine kinase signal transduction, for example, cancer, blood vessel proliferative disorders, fibrotic disorders, and neurodegenerative diseases. In particular, the compounds of the present invention are useful for treatment of mesangial cell proliferative disorders and metabolic diseases, pterigium, arthritis, restenosis, hepatic cirrhosis, atherosclerosis, psoriasis, rosacea, diabetes mellitus, wound healing, inflammation and neurodegenerative diseases and preferably ophthalmic diseases, i.e. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is further directed to pharmaceutical compositions comprising a pharmaceutically effective amount of one or more of the above described compounds and a pharmaceutically acceptable carrier or excipient, wherein said compositions are effective for treating the above diseases and conditions; especially ophthalmic diseases and conditions. Such a composition is believed to modulate signal transduction by a tyrosine kinase, either by inhibition of catalytic activity, affinity to ATP or ability to interact with a substrate.

More particularly, the compositions of the present invention may be included in methods for treating diseases comprising proliferation, fibrotic or metabolic disorders, for example cancer, fibrosis, psoriasis, rosacea, atherosclerosis, arthritis, and other disorders related to abnormal vasculogenesis and/or angiogenesis, such as exudative age related macular degeneration and diabetic retinopathy

The following defined terms are used throughout this specification:

“EtOAc” refers to ethyl acetate

“PDGFR β ” refers to platelet-derived growth factor beta

“PTK” refers to protein tryrosine kinase

“rt” refers to room temperature

“RTK” refers to receptor tyrosine kinase

“VEGFR” refers to vascular endothelial growth factor receptor

“VEGF” refers to vascular endothelial growth factor

“Hydrocarbyl” refers to a hydrocarbon radical having only carbon and hydrogen atoms.

5 Preferably, the hydrocarbyl radical has from 1 to 20 carbon atoms, more preferably from 1 to 12 carbon atoms and most preferably from 1 to 7 carbon atoms.

10 “Substituted hydrocarbyl” refers to a hydrocarbyl radical wherein one or more, but not all, of the hydrogen and/or the carbon atoms are replaced by a halogen, nitrogen, oxygen, sulfur or phosphorus atom or a radical including a halo, nitrogen, oxygen, sulfur or phosphorus atom, e.g. fluoro, chloro, cyano, nitro, dialkylamino, hydroxyl, phosphate, thiol, etc.

15 “Pharmaceutically acceptable salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Pharmaceutically acceptable salts may also refer to those salts which retain the biological effectiveness and properties of the free acid and which
20 are obtained by reaction with inorganic bases such as sodium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide or by organic bases such as tromethamine, choline, diethylamine and lysine and the like.

25 “Alkyl” refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, most preferably 1 to 4 carbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like. The alkyl group may be optionally substituted with one or more substituents are selected from the group consisting of hydroxyl, cyano, alkoxy, =O, =S, NO₂, halogen, dimethyl amino, and SH.

30

“Alkoxy” refers to O-alkyl.

“Alkoxy carbonyl” refers to $-C(O)O\text{-alkyl}$ or $-C(O)O\text{-aryl}$.

“Aryl” refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups. The
5 aryl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxyl, SH, OH, NO₂, amine, thioether, cyano, alkoxy, alkyl, and amino.

“Carbocyclic aryl” refers to an aryl group wherein the ring atoms are carbon.


10

“Heteroaryl” or “heterocyclic aryl” refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen. Thus, heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like.

15


The compounds of this invention may be prepared by the general reaction schemes set forth below.

Scheme 1



5






Scheme 2






10

In particular the compounds of the present invention are selected from the compounds of Table 1, below.

Table 1

Example Number	Structure	Chemical Name
Example 1		(2Z)-3-{4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl}-3-phenylacrylamide
Example 2		(2E)-3-{4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl}-3-(3-methoxyphenyl)acrylamide
Example 3		(2E)-3-{4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl}-3-(4-methoxyphenyl)acrylamide
Example 4		(2Z)-3-{3-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl}-3-phenylacrylamide
Example 5		(2E)-3-{3-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl}acrylamide

Example Number	Structure	Chemical Name
Example 6		(2E)-3-{4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino}phenyl}acrylamide
Example 7		(2Z)-3-{4-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino}phenyl}acrylamide
Example 8		(2E)-3-{3-[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino}phenyl}acrylamide

Biological data for the compounds of the present invention was generated by use of the following assay.

VEGFR2 kinase potency of select analogs was determined by the following assay:



VEGFR2 Kinase Assay:







Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 µg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS + 0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 µL reaction volumes containing 2.7 µM ATP in kinase buffer (50mM Hepes buffer pH 7.4, 20mM MgCl₂, 0.1 mM MnCl₂ and 0.2 mM Na₃VO₄). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO

concentration of 5%. Reactions were initiated by the addition 20 μ l per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, CA). Following a 15 minute incubation at 30⁰ C., the reactions were washed 2 mls per well PBS-T. 100 μ l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μ l of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μ l of 2.5N H₂SO₄ to each well and read using a microplate ELISA reader set at 492 nm. IC₅₀ values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.

TABLE 2

Table 2: VEGFR2 Kinase activity for Select Analogs

Example Number	Structure	VEGFR2 Kinase Assay (IC ₅₀ nM)
Example 1		626
Example 2		945

Example Number	Structure	VEGFR2 Kinase Assay (IC ₅₀ nM)
Example 3		457
Example 4		>10000
Example 5		>10000
Example 6		>10000
Example 7		2790
Example 8		>10000

It has been, surprisingly, found from the above data that;


The compounds of Examples 1, 2, 3, and 7 are preferred as having excellent VEGFR2 potency as shown in this assay.

The compounds of Examples 1, 2 and 3 are more preferred as having even better VEGFR2 potency as shown in this assay.

Finally, the compound of Example 3 is most preferred as having the best VEGFR2 potency as shown in this assay.

The invention is further illustrated by the following non-limiting examples.


Preparation 1



1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(4-iodophenyl)urea

To a solution of 4-iodoaniline (438 mg, 2.0 mmol) in 15.0 mL 1,2-dichloroethane at rt was added 2-fluoro-5-(trifluoromethyl)phenyl isocyanate (0.304 mL, 2.1 mmol). After 50 minutes 3 mL hexane was added, the mixture cooled to 0 °C, the precipitant filtered and rinsed with 10% EtOAc/hexane to give the title compound as a light purple solid (692 mg, 82%). ¹H NMR (DSMO-d₆) δ: 9.26 (s, 1H), 8.90 (d, J = 2.9 Hz, 1H), 8.59 (dd, J = 7.3, 2.3 Hz, 1H), 7.60 - 7.65 (m, 2H), 7.46 - 7.54 (m, 1H), 7.36 - 7.43 (m, 1H), 7.29 - 7.34 (m, 2H).


Preparation 2



1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(3-iodophenyl)urea

To a solution of 3-iodoaniline (438 mg, 2.0 mmol) in 15.0 mL 1,2-dichloroethane at rt was added 2-fluoro-5-(trifluoromethyl)phenyl isocyanate (0.304 mL, 2.1 mmol). After 4 hours the precipitant was filtered and rinsed with 10% EtOAc/hexane to give the title compound as a white solid (602 mg, 71%). ¹H NMR (DSMO-d₆) δ: 9.25 (br. s, 1H), 8.91 (br. s, 1H), 8.57 (dd, J = 7.3, 2.1 Hz, 1H), 8.04 (t, J = 1.9 Hz, 1H), 7.46 - 7.54 (m, 1H), 7.42 (dd, J = 4.5, 2.2 Hz, 1H), 7.35 - 7.40 (m, 1H), 7.28 - 7.33 (m, 1H), 7.06 - 7.14 (m, 1H)

Preparation 3




3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}phenylprop-2-ynamide

To a mixture of propynoic acid amide (41.4 mg, 0.60 mmol), 1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(4-iodophenyl)urea (169.7 mg, 0.40 mmol), triethylamine (0.167 mL, 1.2 mmol), dichlorobis(triphenylphosphine)palladium(II) (22.5 mg, 0.032 mmol), and triphenylphosphine (5.2 mg, 0.020 mmol) in 3.0 mL DMF (degassed) was added copper(I)iodide (7.6 mg, 0.04 mmol) and the reaction stirred at rt for 17 hours. The reaction was combined with a prior test reaction (36.5 mg theoretical yield) and

partitioned between EtOAc and H₂O/brine mixture. The EtOAc layer was washed 3 times with H₂O/brine mixture, then brine, dried with anhydrous Na₂SO₄ and rotary evaporated to a solid. The solid was chromatographed eluting with EtOAc/CHCl₃ and then triturated with EtOAc/hexane to give the title compound as a light tan solid (118.5 mg, 65%). ¹H NMR (DSMO-d₆) δ: 9.45 (s, 1H), 8.98 (d, J = 2.9 Hz, 1H), 8.59 (dd, J = 7.3, 2.1 Hz, 1H), 8.07 (br. s, 1H), 7.59 (br. s., 1H), 7.47 - 7.58 (m, 5H), 7.38 - 7.45 (m, 1H).


Preparation 4



3-{3-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonylamino}phenyl}prop-2-ynamide

To a mixture of propynoic acid amide (41.4 mg, 0.60 mmol), 1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(3-iodophenyl)urea (169.7 mg, 0.40 mmol), triethylamine (0.167 mL, 1.2 mmol), dichlorobis(triphenylphosphine)palladium(II) (22.5 mg, 0.032 mmol), and triphenylphosphine (5.2 mg, 0.020 mmol) in 3.0 mL DMF (degassed) was added copper(I)iodide (7.6 mg, 0.04 mmol) and the reaction stirred at rt for 15 hours. The reaction was partitioned between EtOAc and H₂O/brine mixture. The EtOAc layer was washed 3 times with H₂O/brine mixture, then brine, dried with anhydrous Na₂SO₄ and rotary evaporated to a solid. The solid was triturated with hot MeOH and then triturated with hot EtOAc to give the title compound as a light tan solid (107.4 mg, 74%). ¹H NMR (DSMO-d₆) δ: 9.33 (s, 1H), 8.95 (d, J = 2.1 Hz, 1H), 8.60 (dd, J = 7.3, 2.1 Hz, 1H), 8.17 (br. s., 1H), 7.87 (s, 1H), 7.67 (br. s., 1H), 7.37 - 7.55 (m, 4H), 7.17 - 7.25 (m, 1H)


Example 1



(2Z)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-phenylacrylamide

A mixture of 3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}prop-2-ynamide (31.0 mg, 0.085 mmol), iodobenzene (0.010 mL, 0.089 mmol), diethylamine (0.029 mL, 0.281 mmol), formic acid (0.0083 mL, 0.221 mmol), and bis(dibenzylideneacetone)palladium(0) (3.4 mg, 0.006 mmol) in 1.1 mL EtOAc (degassed) was heated at 75 °C. After 2 hours, an additional 2 mg bis(dibenzylideneacetone)palladium(0) was added and the reaction continued for 18 hours. The reaction was partitioned between EtOAc and H₂O/brine mixture. The EtOAc layer was washed with dilute aqueous HCl, then aqueous Na₂CO₃, brine, dried with anhydrous Na₂SO₄ and rotary evaporated. The crude product was chromatographed eluting with EtOAc/CHCl₃ and the resulting solid again chromatographed with MeOH/CHCl₃ to give the title compound as an off-white solid (8.8 mg, 23%). ¹H NMR (Acetone-d₆) δ: 8.79 (dd, J = 7.5, 2.2 Hz, 1H), 8.43 (d, J = 2.9 Hz, 1H), 8.41 (s, 1H), 7.39 - 7.44 (m, 2H), 7.27 - 7.39 (m, 7H), 7.11 - 7.16 (m, 3H), 6.76 (br. s., 1H), 6.49 (s, 1H)


Example 2



(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-(3-methoxyphenyl)acrylamide

A mixture of 3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}prop-2-ynamide (31.0 mg, 0.085 mmol), 3-iodoanisole (0.010 mL, 0.089 mmol), diethylamine (0.029 mL, 0.281 mmol), formic acid (0.0083 mL, 0.221 mmol), and bis(dibenzylideneacetone)palladium(0) (3.4 mg, 0.006 mmol) in 1.4 mL EtOAc (degassed) was heated at 75 °C for 17 hours. The reaction was partitioned between EtOAc and H₂O/brine mixture. The EtOAc layer was washed with dilute aqueous HCl, then aqueous NaHCO₃, brine, and dried with anhydrous Na₂SO₄ to give 20 mL of EtOAc solution of crude material. The EtOAc solution was filtered past a plug of silica gel eluting with EtOAc, evaporated, and the resulting solid chromatographed eluting with CHCl₃/MeOH to give the title compound as a light tan solid (12.0 mg, 30%). ¹H NMR (Acetone-d₆) δ: 8.80 (d, J = 5.9 Hz, 1H), 8.46 (s, 1H), 8.42 (d, J = 2.6 Hz, 1H), 7.33 - 7.47 (m, 4H), 7.23 - 7.29 (m, 1H), 7.15 (d, J = 8.5 Hz, 2H), 6.91 - 7.00 (m, 2H), 6.82 - 6.87 (m, 2H), 6.65 (br. s., 1H), 6.47 (s, 1H), 3.77 (s, 3H).

Example 3




(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-(4-methoxyphenyl)acrylamide

A mixture of 3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}prop-2-ynamide (31.0 mg, 0.085 mmol), 4-iodoanisole (0.010 mL, 0.089 mmol), diethylamine (0.029 mL, 0.281 mmol), formic acid (0.0083 mL, 0.221 mmol), and bis(dibenzylideneacetone)palladium(0) (3.4 mg, 0.006 mmol) in 1.4 mL EtOAc

(degassed) was heated at 75 °C for 20 hours. The reaction was partitioned between EtOAc and H₂O/brine mixture. The EtOAc layer was washed with dilute aqueous HCl, then aqueous NaHCO₃, brine, and dried with anhydrous Na₂SO₄ to give 20 mL of EtOAc solution of crude material. The EtOAc solution was filtered past a plug of silica gel eluting with EtOAc, evaporated, and the resulting solid chromatographed eluting with EtOAc/CHCl₃ to give the title compound as a grey-purple solid (12.5 mg, 31%). ¹H NMR (Acetone-d₆) δ: 8.80 (d, J = 7.6 Hz, 1H), 8.42 (s, 2H), 7.32 - 7.45 (m, 4H), 7.21 - 7.26 (m, 2H), 7.10 - 7.16 (m, 2H), 6.98 (br. s., 1H), 6.88 - 6.94 (m, 2H), 6.63 (br. s., 1H), 6.43 (s, 1H), 3.81 (s, 3H).

Example 4




(2Z)-3-{3-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonylamino}phenyl}-3-phenylacrylamide

A mixture of 3-{3-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonylamino}phenyl}prop-2-ynamide (31.0 mg, 0.085 mmol), iodobenzene (0.010 mL, 0.089 mmol), diethylamine (0.029 mL, 0.281 mmol), formic acid (0.0083 mL, 0.221 mmol), and bis(dibenzylideneacetone)palladium(0) (3.4 mg, 0.006 mmol) in 1.1 mL EtOAc (degassed) was heated at 75 °C for 16 hours. The reaction was partitioned between EtOAc and H₂O/brine mixture. The EtOAc layer was washed with H₂O/brine mixture, brine, dried with anhydrous Na₂SO₄ and rotary evaporated. The crude material was chromatographed eluting with EtOAc/CHCl₃ to give the higher R_f material as an off-white solid. The solid was recrystallized from EtOAc/hexane to give the title compound as a white solid (7.5 mg, 20%). ¹H NMR (CD₃CN) δ: 8.54 - 8.58 (m, 1H), 7.89 (s, 1H), 7.71

(d, J = 3.2 Hz, 1H), 7.14 - 7.39 (m, 10H), 6.78 - 6.82 (m, 1H), 6.39 (s, 1H), 6.14 (br. s, 1H), 5.79 (br. s, 1H).


Example 5



(2E)-3-{3-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide

The lower R_f eluting material from the chromatography of the crude reaction mixture from Example 4 was obtained as an off-white solid and then recrystallized from EtOAc/hexane to give the title compound as a white solid (8.2 mg). ¹H NMR (CD₃CN) δ: 8.55 - 8.60 (m, 1H), 7.84 (s, 1H), 7.61 - 7.64 (m, 2H), 7.45 - 7.50 (m, 1H), 7.28 - 7.34 (m, 2H), 7.24 (t, J = 7.8 Hz, 1H), 7.12 - 7.17 (m, 1H), 6.74 (d, J = 12.6 Hz, 1H), 6.31 (br. s, 1H), 6.03 (d, J = 12.6 Hz, 1H), 5.91 (br. s., 1H).


Example 6



(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide

A mixture of acrylamide (6.2 mg, 0.087 mmol), 1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(4-iodophenyl)urea (9.2 mg, 0.022 mmol), and palladium(II) acetate (1.9 mg, 0.0087 mmol) in 0.6 mL degassed DMF:triethylamine (1:1) was reacted at 90 °C. After 2.5 hours, the heating was stopped and the reaction stored at rt for 3 days in the dark. Then a catalytic amount of palladium(II) acetate was added and the heating resumed at 90 °C for 7.5 hours, then the temperature lowered to 65 °C for 16 hours. The reaction was partitioned between EtOAc and H₂O/brine mixture. The EtOAc layer was washed with dilute aqueous HCl, then aqueous NaHCO₃, brine, dried with anhydrous Na₂SO₄ and evaporated. The resulting solid was chromatographed eluting with CHCl₃/MeOH and then triturated with a CHCl₃ plus 40% EtOAc/hexane mixture to give the title compound as a light tan solid (3.9 mg, 49%). ¹H NMR (Acetone-d₆) δ: 8.76 - 8.83 (m, 2H), 8.40 (d, J = 2.6 Hz, 1H), 7.58 - 7.63 (m, 2H), 7.37 - 7.57 (m, 5H), 6.91 (br. s, 1H), 6.63 (d, J = 15.8 Hz, 1H), 6.32 (br. s, 1H)

Example 7




(2Z)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide

A mixture of 3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}prop-2-ynamide (12.2 mg, 0.033 mmol), 0.005 mL quinoline, and 4 mg Lindlar catalyst in 1.5 mL EtOAc was reacted under a balloon of hydrogen. After 1.75 hours, an additional catalytic amount of Lindlar catalyst was added and the reaction continued for an additional 1 hour. The reaction mixture was partitioned between EtOAc and dilute aqueous HCl, the EtOAc layer washed with H₂O, brine, dried with Na₂SO₄ and

evaporated. The crude material was chromatographed eluting with hexane/acetone to give the title compound as a white solid (10.3 mg, 84%). ^1H NMR (Acetone- d_6) δ : 8.79 (d, J = 7.9 Hz, 1H), 8.69 (br. s., 1H), 8.37 (br. s., 1H), 7.75 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.8 Hz, 2H), 7.35 - 7.43 (m, 2H), 6.93 (br. s., 1H), 6.64 (d, J = 12.9 Hz, 1H), 6.41 (br. s., 1H), 5.97 (d, J = 12.9 Hz, 1H)

Example 8



(2E)-3-{3-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide

A mixture of acrylamide (24.7 mg, 0.347 mmol), 1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(3-iodophenyl)urea (36.8 mg, 0.087 mmol), and palladium(II) acetate (7.8 mg, 0.035 mmol) in 0.8 mL degassed DMF:triethylamine (1:1) was reacted at 75 °C. After 14.5 hours a catalytic amount of palladium(II) acetate was added, the temperature increased to 85 °C, and the reaction continued for an additional 3.5 hours. The reaction was partitioned between EtOAc and H₂O/brine mixture. The EtOAc layer was washed with dilute aqueous HCl, then aqueous NaHCO₃, brine, dried with anhydrous Na₂SO₄ and evaporated. The resulting solid was triturated with CHCl₃/MeOH to give the title compound as a light tan solid (8.2 mg, 26%). ^1H NMR (Acetone- d_6) δ : 8.73 - 8.82 (m, 2H), 8.41 (br. s., 1H), 7.94 (s, 1H), 7.53 (d, J = 15.7 Hz, 1H), 7.30 - 7.48 (m, 4H), 7.21 - 7.27 (m, 1H), 7.10 (br. s., 1H), 6.70 (d, J = 15.7 Hz, 1H), 6.41 (br. s., 1H).

The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention only.

Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. For example, the novel compounds of this invention include any compound which is a (2E) or (2Z)-3-{4-[({[aryl]amino}carbonyl)amino]phenyl}-3-acrylamide or phenylacrylamide or lower alkyl acrylamide or phenylacrylamide and, in particular, a (2E) or (2Z)-3-{4-[({[halo-substituted and/or halo lower alkyl-substituted aryl]amino}carbonyl)amino]phenyl}-3- acrylamide or phenylacrylamide or lower alkyl acrylamide or phenylacrylamide and binds to a tyrosine kinase receptor, e.g. a VEGF and/or PDGF receptor.


These compounds may be prepared and tested for tyrosine kinase inhibiting activity by the preparatory methods and assays disclosed above.

Such modifications are intended to fall within the scope of the appended claims.

All references cited herein are hereby incorporated by reference in their entirety for all purposes. Also, the compounds of the present invention may be tested by the various in-vitro and in-vivo assays disclosed in such references to demonstrate the claimed utilities.

We claim:

1. A compound of formula I:



I

or a pharmaceutically acceptable salt thereof; wherein:

R^1 is selected from the group consisting of hydrogen and lower alkyl;


R^2 is selected from the group consisting of hydrogen and lower alkyl;

R^3 is selected from the group consisting of hydrogen, alkyl, aryl and substituted aryl;

R^4 is selected from the group consisting of hydrogen, C_1 to C_8 alkyl, $(\text{CR}^6\text{R}^7)_p\text{NR}^8\text{R}^9$, $(\text{CR}^6\text{R}^7)_p\text{C}(\text{O})\text{OR}^8$ and $(\text{CR}^6\text{R}^7)_p\text{OR}^8$;

Ar^1 is aryl;

X is



R^5 is aryl;

R^6 is selected from the group consisting of hydrogen, lower alkyl, halogen, trifluoromethyl and hydroxyl;

R^7 selected from the group consisting of hydrogen, lower alkyl, halogen, trifluoromethyl and hydroxyl;

R⁸ is selected from the group consisting of hydrogen and lower alkyl

R⁹ is selected from the group consisting of hydrogen and lower alkyl, or

R⁸ and R⁹ may be taken together with N to form a heterocyclic ring; and

p is an integer of from 1 to 6.

2. The compound of claim 1, wherein R¹ and R² are hydrogen.
3. The compound of claim 1, wherein R³ is selected from the group consisting of hydrogen, phenyl and alkyloxyphenyl.
4. The compound of claim 1, wherein R⁴ is hydrogen;
5. The compound of claim 1, wherein Ar¹ is phenyl.
6. The compound of claim 1, wherein, X is –HN-C(O)-NH-.
7. The compound of claim 1, wherein, R⁵ is selected from the group consisting of phenyl and halo-substituted and halo lower alkyl-substituted phenyl.
8. The compound of claim 1, wherein R⁵ is a fluoro, trifluoromethylphenyl.
9. The compound of claim 1 selected from the group consisting of:
(2Z)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl]amino}phenyl}-3-phenylacrylamide;
(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl]amino}phenyl}-3-(3-methoxyphenyl)acrylamide;
(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl]amino}phenyl}-3-(4-methoxyphenyl)acrylamide;

(2Z)-3-{3-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-phenylacrylamide;
(2E)-3-{3-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide;
(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide;
(2Z)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide; and
(2E)-3-{3-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide; or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 selected from the group consisting of:

(2Z)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-phenylacrylamide;
(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-(3-methoxyphenyl)acrylamide;
(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-(4-methoxyphenyl)acrylamide; and
(2Z)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}acrylamide; or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 selected from the group consisting of:

(2Z)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-phenylacrylamide;
(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-(3-methoxyphenyl)acrylamide; and
(2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-(4-methoxyphenyl)acrylamide;
or a pharmaceutically acceptable salt thereof.


12. The compound of claim 1 that is (2E)-3-{4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenyl}-3-(4-methoxyphenyl)acrylamide; or a pharmaceutically acceptable salt thereof.

13. A compound that is a (2E) or (2Z)-3-{4-[(phenyl)amino]carbonyl}amino]phenyl}-3-acrylamide or phenylacrylamide, or lower alkyl acrylamide or phenylacrylamide; or a pharmaceutically acceptable salt thereof, and binds to a VEGF and/or a PDGF receptor.

14. A compound according to claim 13 that is a (2E) or (2Z)-3-{4-[(halo-substituted and/or halo lower alkyl-substituted phenyl)amino]carbonyl}amino]phenyl}-3-acrylamide, or phenylacrylamide or lower alkyl acrylamide; or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

16. A method for treating disease selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases, and ophthalmic diseases, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound represented by formula I:



I

or a pharmaceutically acceptable salt thereof; wherein:

R^1 is selected from the group consisting of hydrogen and lower alkyl;


R^2 is selected from the group consisting of hydrogen and lower alkyl;

R^3 is selected from the group consisting of hydrogen, alkyl, aryl and substituted aryl;

R^4 is selected from the group consisting of hydrogen, C_1 to C_8 alkyl, $(CR^6R^7)_pNR^8R^9$, $(CR^6R^7)_pC(O)OR^8$ and $(CR^6R^7)_pOR^8$;

Ar^1 is aryl;

X is



R^5 is aryl;

R^6 is selected from the group consisting of hydrogen, lower alkyl, halogen, trifluoromethyl and hydroxyl;

R^7 selected from the group consisting of hydrogen, lower alkyl, halogen, trifluoromethyl and hydroxyl;

R^8 is selected from the group consisting of hydrogen and lower alkyl

R^9 is selected from the group consisting of hydrogen and lower alkyl, or

R^8 and R^9 may be taken together with N to form a heterocyclic ring; and

p is an integer of from 1 to 6.

17. The method of claim 16 wherein the blood vessel proliferative disorder is selected from the group consisting of diabetic retinopathy, exudative age-related macular degeneration, retinopathy of prematurity, pterigium, rosacea, arthritis and restenosis; the fibrotic disorder is selected from the group consisting of hepatic cirrhosis and atherosclerosis; the mesangial cell proliferative disorder is selected from the group consisting of glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection and glomerulopathies; the metabolic disease is selected from the group consisting of psoriasis, diabetes mellitus, wound healing, inflammation and neurodegenerative diseases; and the ophthalmic disease is selected from the group consisting of diabetic retinopathy, exudative age-related macular degeneration and retinopathy of prematurity.

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2014/021345

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07C275/30 A61K31/17
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/21577 A2 (TAKEDA CHEMICAL INDUSTRIES LTD [JP]; KATO KANEYOSHI [JP]; TERAUCHI JUN) 29 March 2001 (2001-03-29) page 137; example 74 abstract	1-5, 15, 16
X	----- WO 2005/030705 A1 (METHYLGENE INC [CA]; MORADEI OSCAR [CA]; PAQUIN ISABELLE [CA]; LEIT SI) 7 April 2005 (2005-04-07) example 18 abstract	1-5, 15, 16
X	----- EP 2 070 928 A1 (NERVIANO MEDICAL SCIENCES SRL [IT]) 17 June 2009 (2009-06-17) paragraphs [[0262]], [[0263]], [[0277]], [[0279]], [[0280]], [[0281]] the whole document ----- -/-	1-4, 7, 15, 16

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

19 May 2014

Date of mailing of the international search report

28/05/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Tabanella, Stefania

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2014/021345

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/098458 A2 (ASTERAND UK LTD [GB]; COLEMAN ROBERT [GB]; MIDDLEMISS DAVID [GB]) 13 August 2009 (2009-08-13) example 7 abstract	1-5,7,8, 15,16
X	----- WO 2010/092440 A1 (INST NAT SANTE RECH MED [FR]; FAJAS LLUIS [FR]; CHAVEY CARINE [FR]) 19 August 2010 (2010-08-19) (E)-N-[3-[(2-aminocarbonyl)thenyl]]-2-hydr oxyphenyl]-N'-(2-bromophenyl)urea; page 8 the whole document	1-7,15, 16
X	----- EP 2 060 565 A1 (4SC AG [DE]) 20 May 2009 (2009-05-20) the whole document	13,14
A	----- page 21 - page 22	1-12, 15-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/021345

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0121577	A2	29-03-2001	AU 7315700 A CA 2386474 A1 CO 5251437 A1 EP 1218336 A2 PE 06132001 A1 US 7115750 B1 US 2007173498 A1 WO 0121577 A2	24-04-2001 29-03-2001 28-02-2003 03-07-2002 21-05-2001 03-10-2006 26-07-2007 29-03-2001
WO 2005030705	A1	07-04-2005	AU 2004276337 A1 CA 2539117 A1 EP 1663953 A1 JP 4809228 B2 JP 5127402 B2 JP 2007506785 A JP 2008094847 A KR 20060065730 A US 2008132459 A1 WO 2005030704 A1 WO 2005030705 A1	07-04-2005 07-04-2005 07-06-2006 09-11-2011 23-01-2013 22-03-2007 24-04-2008 14-06-2006 05-06-2008 07-04-2005 07-04-2005
EP 2070928	A1	17-06-2009	NONE	
WO 2009098458	A2	13-08-2009	AU 2009211172 A1 CA 2713547 A1 CN 101939288 A EP 2238101 A2 JP 2011510965 A KR 20100131976 A US 2010331410 A1 WO 2009098458 A2	13-08-2009 13-08-2009 05-01-2011 13-10-2010 07-04-2011 16-12-2010 30-12-2010 13-08-2009
WO 2010092440	A1	19-08-2010	NONE	
EP 2060565	A1	20-05-2009	CA 2705922 A1 EP 2060565 A1 EP 2220042 A1 US 2011065734 A1 WO 2009063054 A1	22-05-2009 20-05-2009 25-08-2010 17-03-2011 22-05-2009